The Recall Desk
HighFDA (Drugs)·D-0646-2025·Announced 2025-09-24

[pending] bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Dose Syringe, Fagron S

Pending LLM rewrite. Source: FDA_DRUG D-0646-2025.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Pending LLM scoring against the rubric.

Plain-English summary

Lack of Assurance of Sterility

The recalled product

Product
bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Dose Syringe, Fagron Sterile Services, 8710 E 34th St N. Wichita, KS 67226
Manufacturer
Fagron Compounding Services
Category
Drug — Drugs

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • Lot #: C274-000044756
  • C274-000044757
  • Exp 8-30-2025
  • C274-000044832
  • C274-000044833
  • Exp 9-4-2025
  • C274-000044882
  • C274-000044883
  • Exp 9-6-2025
  • C274-000044972
  • Exp 9-8-2025
  • C274-000045004
  • C274-000045005
  • Exp 9-18-2025 C274-000045108
  • exp. date 9-13-2025 C274-000045109
  • exp. date 9-13-2025 C274-000045136
  • exp. date 9-14-2025 C274-000045137
  • exp. date 9-14-2025 C274-000045289
  • exp. date 9-20-2025 C274-000045290
  • exp. date 9-20-2025 C274-000045350

Distribution

Distributed nationwide across the United States.

Related recalls

Same category